Cargando…
Leishmania Vesicle-Depleted Exoproteome: What, Why, and How?
Leishmaniasis, a vector-borne parasitic protozoan disease, is among the most important neglected tropical diseases. In the absence of vaccines, disease management is challenging. The available chemotherapy is suboptimal, and there are growing concerns about the emergence of drug resistance. Thus, a...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781507/ https://www.ncbi.nlm.nih.gov/pubmed/36557688 http://dx.doi.org/10.3390/microorganisms10122435 |
_version_ | 1784857091185311744 |
---|---|
author | Esteves, Sofia Costa, Inês Luelmo, Sara Santarém, Nuno Cordeiro-da-Silva, Anabela |
author_facet | Esteves, Sofia Costa, Inês Luelmo, Sara Santarém, Nuno Cordeiro-da-Silva, Anabela |
author_sort | Esteves, Sofia |
collection | PubMed |
description | Leishmaniasis, a vector-borne parasitic protozoan disease, is among the most important neglected tropical diseases. In the absence of vaccines, disease management is challenging. The available chemotherapy is suboptimal, and there are growing concerns about the emergence of drug resistance. Thus, a better understanding of parasite biology is essential to generate new strategies for disease control. In this context, in vitro parasite exoproteome characterization enabled the identification of proteins involved in parasite survival, pathogenesis, and other biologically relevant processes. After 2005, with the availability of genomic information, these studies became increasingly feasible and revealed the true complexity of the parasite exoproteome. After the discovery of Leishmania extracellular vesicles (EVs), most exoproteome studies shifted to the characterization of EVs. The non-EV portion of the exoproteome, named the vesicle-depleted exoproteome (VDE), has been mostly ignored even if it accounts for a significant portion of the total exoproteome proteins. Herein, we summarize the importance of total exoproteome studies followed by a special emphasis on the available information and the biological relevance of the VDE. Finally, we report on how VDE can be studied and disclose how it might contribute to providing biologically relevant targets for diagnosis, drug, and vaccine development. |
format | Online Article Text |
id | pubmed-9781507 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97815072022-12-24 Leishmania Vesicle-Depleted Exoproteome: What, Why, and How? Esteves, Sofia Costa, Inês Luelmo, Sara Santarém, Nuno Cordeiro-da-Silva, Anabela Microorganisms Review Leishmaniasis, a vector-borne parasitic protozoan disease, is among the most important neglected tropical diseases. In the absence of vaccines, disease management is challenging. The available chemotherapy is suboptimal, and there are growing concerns about the emergence of drug resistance. Thus, a better understanding of parasite biology is essential to generate new strategies for disease control. In this context, in vitro parasite exoproteome characterization enabled the identification of proteins involved in parasite survival, pathogenesis, and other biologically relevant processes. After 2005, with the availability of genomic information, these studies became increasingly feasible and revealed the true complexity of the parasite exoproteome. After the discovery of Leishmania extracellular vesicles (EVs), most exoproteome studies shifted to the characterization of EVs. The non-EV portion of the exoproteome, named the vesicle-depleted exoproteome (VDE), has been mostly ignored even if it accounts for a significant portion of the total exoproteome proteins. Herein, we summarize the importance of total exoproteome studies followed by a special emphasis on the available information and the biological relevance of the VDE. Finally, we report on how VDE can be studied and disclose how it might contribute to providing biologically relevant targets for diagnosis, drug, and vaccine development. MDPI 2022-12-08 /pmc/articles/PMC9781507/ /pubmed/36557688 http://dx.doi.org/10.3390/microorganisms10122435 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Esteves, Sofia Costa, Inês Luelmo, Sara Santarém, Nuno Cordeiro-da-Silva, Anabela Leishmania Vesicle-Depleted Exoproteome: What, Why, and How? |
title | Leishmania Vesicle-Depleted Exoproteome: What, Why, and How? |
title_full | Leishmania Vesicle-Depleted Exoproteome: What, Why, and How? |
title_fullStr | Leishmania Vesicle-Depleted Exoproteome: What, Why, and How? |
title_full_unstemmed | Leishmania Vesicle-Depleted Exoproteome: What, Why, and How? |
title_short | Leishmania Vesicle-Depleted Exoproteome: What, Why, and How? |
title_sort | leishmania vesicle-depleted exoproteome: what, why, and how? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781507/ https://www.ncbi.nlm.nih.gov/pubmed/36557688 http://dx.doi.org/10.3390/microorganisms10122435 |
work_keys_str_mv | AT estevessofia leishmaniavesicledepletedexoproteomewhatwhyandhow AT costaines leishmaniavesicledepletedexoproteomewhatwhyandhow AT luelmosara leishmaniavesicledepletedexoproteomewhatwhyandhow AT santaremnuno leishmaniavesicledepletedexoproteomewhatwhyandhow AT cordeirodasilvaanabela leishmaniavesicledepletedexoproteomewhatwhyandhow |